Scientific Program
| Thursday, September 19, 2024 | |||
| Hall A IACH |
|||
| 08:30-09:00 | Welcome Coffee | ||
| 09:00-10:20 | Transplant Workshop Part I | ||
| Moderators: Mohamad Mohty, France; Arnon Nagler, Israel | |||
| 09:00-09:20 | How to optimize the choice of the stem cell source and donor: Annalissa Ruggeri, Italy |
||
| 09:20-09:40 | Optimal choice of the conditioning regimen: Arnon Nagler, Israel |
||
| 09:40-10:00 | Optimal GVHD prophylaxis: María Queralt Salas, Spain |
||
| 10:00-10:20 | Diagnosis and management of acute GVHD: Florent Malard, France |
||
| 10:20-10:30 | Short Break | ||
| 10:30-12:00 | Transplant Workshop Part II | ||
| Moderators: Mohamad Mohty, France; Arnon Nagler, Israel; Zinaida Perić, Croatia | |||
| 10:30-10:50 | Chronic GVHD: prevention and management of long-term complications: Zinaida Perić, Croatia |
||
| 10:50-11:10 | Diagnosis and management of chronic GVHD: Mohamad Mohty, France |
||
| 11:10-11:30 | Early transplant complications: a focus on VOD diagnosis: Rafael Duarte, Spain |
||
| 11:30-12:00 | Breaking bad news: communication skills in case of life-threatening clinical conditions Panel discussion: All session faculty + Antonio Pagliuca, UK and Michelle Kenyon, UK |
||
| 12:00-12:45 | Lunch Break | ||
| Hall A IACH + COLYM |
Hall B COMydAL + MPNCo&D |
||
| 12:45-13:00 | Meeting Opening Message by the IACH Co-Chairs |
||
| 13:00-14:30 | Session 1a: Indolent lymphoma |
13:00-14:30 | Session 1b: Controversies in lower risk MDS |
| Chair: Stefano Luminari, Italy | Moderators: Amer Zeidan, USA; Valeria Santini, Italy | ||
| 13:00-13:15 | Case report: Deferred Diagnosis: The Consequences of Excisional Biopsy Deferral in Follicular Lymphoma Presented by: Shea-Lee Godin, USA |
13:00-13:15 | How do we define lower risk MDS in 2024? Matteo Della Porta, Italy |
| 13:15-13:30 | Q&A | 13:15-13:30 | Therapy of thrombocytopenic lower risk MDS? Ioannis Kotsianidis, Greece |
| 13:30-13:50 | Marginal zone lymphoma (MZL): Luca Arcaini, Italy |
13:30-13:45 | What is the first line therapy for non-del5q anaemic LR-MDS: Sophie Park, France |
| 13:50-14:10 | Follicular lymphoma (FL): Wendy Osborne, UK |
13:45-14:00 | Is sequencing or combining therapies the better approach for lower risk MDS? María Díez Campelo, Spain |
| 14:10-14:30 | Panel discussion: All session faculty | 14:00-14:15 | How should we measure therapeutic benefit in lower risk MDS? Pierre Fenaux, France |
| 14:15-14:30 | Panel discussion: All session faculty | ||
| 14:30-14:50 | Coffee Break | ||
| 14:50-15:20 | Essential thrombocythemia: Unmet needs and impact of novel therapies Industry Supported Meet the Expert Session (CLICK TO VIEW ON DEMAND) |
||
| 15:20-15:30 | Coffee Break continued … | ||
| 15:30-17:00 | Session 2a: Hodgkin lymphoma |
15:30-17:00 | Session 2b: Treatment of intermediate/higher-risk MF |
| Chair: Mehdi Hamadani, USA | Moderators: Florian Heidel, Germany; Tania Jain, USA | ||
| 15:30-15:45 | Case report: Extranodal CHL Presented by: Shira Kimberley, South Africa |
15:30-15:50 | Review of JAKi in treatment of MF which drug when to use: Naveen Pemmaraju, USA |
| 15:45-16:00 | Q&A | 15:50-16:10 | Debate: Future therapy of MF should be a combination there is enough evidence Yes: Adam Mead, UK No: Florian Heidel, Germany |
| 16:00-16:15 | 1st line treatment young/fit: Farrukh Awan, USA |
16:10-16:30 | SCT in MF: Review of current practice USA perspective – we will do more transplants: Tania Jain, USA |
| 16:15-16:30 | 1st line treatment old/unfit: Graham Collins, UK |
16:30-16:50 | SCT in MF: Global perspective and reflections – where do we stand? Arnon Nagler, Israel |
| 16:30-16:45 | Best salvage in R/R Hodgkin: Nilanjan Ghosh, USA |
16:50-17:00 | Panel discussion: All session faculty |
| 16:45-17:00 | Panel discussion: All session faculty | ||
| 17:00-17:10 | Technical Break | ||
| 17:10-18:40 | Session 3a: Diffuse large B cell lymphoma (DLBCL) |
17:10-18:40 | Session 3b: Controversies in higher risk MDS |
| Chair: Anna Sureda, Spain | Moderators: Amer Zeidan, USA; Valeria Santini, Italy | ||
| 17:10-17:25 | Case report: DLBCL second relapse in peripheral nervous system candidate to CAR-T Presented by: Lorenzo Comba, Italy |
17:10-17:25 | Should we care about MRD in higher risk MDS? Arjan van de Loosdrecht, Netherlands |
| 17:25-17:40 | Q&A | 17:25-17:40 | How can we stop phase 3 trials from failing in higher risk MDS? Lionel Adès, France |
| 17:40-17:55 | 1st line treatment: Andrew Davies, UK |
17:40-17:55 | How does venetoclax fit in the management of higher risk MDS? Maximilian Stahl, USA |
| 17:55-18:10 | Bispecific moAb: Catherine Thieblemont, France |
17:55-18:10 | Is immune checkpoint inhibition dead in higher-risk MDS and AML? Shahram Kordasti, UK |
| 18:10-18:25 | CAR T: Mariana Bastos-Oreiro, Spain |
18:10-18:25 | Are oral HMAs a game changer in higher risk MDS? Valeria Santini, Italy |
| 18:25-18:40 | Panel discussion: All session faculty | 18:25-18:40 | Panel discussion: All session faculty |
| Friday, September 20, 2024 | |||
| Hall A IACH + COLYM |
Hall B COMydAL + MPNCo&D |
||
| 08:15-08:30 | Welcome Coffee | ||
| 08:30-10:00 | IACH Session: Sexual and emotional life in patients with hematological malignancies | ||
| Moderators: Mohamad Mohty, France; Tamim Alsuliman, France | |||
| 08:30-08:40 | Opening remarks: Emma Cookson, UK |
||
| 08:40-08:55 | Introduction and unmet needs: Tamim Alsuliman, France |
||
| 08:55-09:10 | Diagnosis and treatment of sexual health-related issues: Laurence Quarez-Blaise, France |
||
| 09:10-09:25 | Sexual health-related psychological and emotional life post allogeneic stem cell transplantation: Zinaida Perić, Croatia |
||
| 09:25-09:45 | Specific concerns: STIs, adolescents and young adults: Tamim Alsuliman, France |
||
| 09:45-10:00 | Panel discussion: All session faculty + Didier Blaise, France |
||
| 10:00-10:30 | Special IACH Lecture: How to get published Junia V. Melo, Australia |
||
| 10:30-11:00 | Coffee Break | ||
| 11:00-12:30 | Session 4a: T cell non-Hodgkin lymphoma (T-NHL) |
11:00-12:30 | Session 4b: Essential thrombocytosis (ET) in 2024: Current and future directions |
| Chair: Mehdi Hamadani, USA | Moderator: Claire Harrison, UK | ||
| 11:00-11:15 | Case report: NK/T Cell Lymphoma in the Setting of Acute Epstein-Barr Virus Complicated by Hemophagocytic Lymphohistiocytosis Presented by: Ekta Panjrolia, USA |
11:00-11:20 | Management of fatigue for MPN patients Claire Woodley, UK |
| 11:15-11:30 | Q&A | 11:20-11:40 | Update for treatment of higher-risk ET: Claire Harrison, UK |
| 11:30-11:50 | BV-CHP & beyond in 1st line T-NHL: Matthew Lunning, USA |
11:40-12:00 | Debate: Should JAK2-ET be treated differently from CALR-ET? Yes: Anna Godfrey, UK No, all patients with ET should be treated in a homogeneous way: Francesca Palandri, Italy |
| 11:50-12:10 | Checkpoint inhibition or allografting for R/R NK/T-cell lymphomas: Philipp Berning, Germany |
12:00-12:20 | CALR: A new era of molecular targeting in ET: Review of pre-clinical & clinical data: Bethan Psaila, UK |
| 12:10-12:30 | Panel discussion: All session faculty | 12:20-12:30 | Panel discussion: All session faculty |
| 12:30-13:00 | IACH Awards | ||
| Presented by: Mohamad Mohty, France; Arnon Nagler, Israel | |||
| H.J. Khoury Excellence in Research Award | |||
| IACH 2024 Special Achievement Award | |||
| Christian Caillot Clinical Research Award | |||
| 13:00-13:45 | Lunch Break | ||
| 13:45-14:45 | Charting Horizons: Advancing Care for Relapse/Refractory Mantel Cell Lymphoma Patients Industry Supported Lunch Symposium |
||
| 14:45-15:00 | Technical Break | ||
| 15:00-16:30 | Session 5a: Chronic lymphocytic leukemia (CLL) |
15:00-16:30 | Session 5b: Controversies in classification, risk stratification and response assessment in AML |
| Chair: Mohamed Kharfan-Dabaja, USA | Moderator: Amer Zeidan, USA | ||
| 15:00-15:15 | Case report: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma of the Prostate Presented by: Zein Sheikh, Saudi Arabia |
15:00-15:15 | How do we risk stratify older patients with AML? Christoph Röllig, Germany |
| 15:15-15:30 | Q&A | 15:15-15:30 | What decisions should be made based on MRD in AML? Coleman Lindsley, USA |
| 15:30-15:50 | Front line therapy for CLL: Farrukh Awan, USA |
15:30-15:45 | Can (or should) response criteria of MDS and AML be harmonized? Lisa Pleyer, Austria |
| 15:50-16:10 | Transplant and cellular therapies in CLL: Olivier Tournilhac, France |
15:45-16:00 | Should we have two pathologic systems for AML? Alexa Siddon, USA |
| 16:10-16:30 | Panel discussion: All session faculty | 16:00-16:30 | Panel discussion: All session faculty |
| 16:30-17:00 | Coffee Break | ||
| 17:00-18:30 | Session 6a: Minimal residual disease (MRD) |
17:00-18:30 | Session 6b: MPN special situations and future directions |
| Chair: Stefano Luminari, Italy | Moderators: Ruben Mesa, USA; Deepti Radia, UK | ||
| 17:00-17:20 | Positron emission tomography (PET): Stephane Chauvie, Italy |
17:00-17:15 | Inflammation and MPNs: Novel observations: Shahram Kordasti, UK |
| 17:20-17:40 | Mantle cell lymphoma (MCL): Christiane Pott, Germany |
17:15-17:30 | Pre-fibrotic MF: State-of-the-art updates: Ruben Mesa, USA |
| 17:40-18:00 | Present and future of response adapted therapies: Andrea Gallamini, France |
17:30-17:45 | HES: Clinical updates and treatment paradigm: Andreas Reiter, Germany |
| 18:00-18:30 | Panel discussion: All session faculty | 17:45-18:00 | Systemic mastocytosis: Updates on clinical trials: Deepti Radia, UK |
| 18:00-18:30 | Panel discussion: All session faculty | ||
| Saturday, September 21, 2024 | |||
| Hall A IACH + COLYM |
Hall B COMydAL + MPNCo&D |
||
| 08:15-08:30 | Welcome Coffee | ||
| 08:30-10:00 | Session 7a: Mantle cell lymphoma (MCL) |
08:30-10:00 | Session 7b: Controversies in the management of AML |
| Chair: Mohamed Kharfan-Dabaja, USA | Moderator: Maximilian Stahl, USA |
||
| 08:30-08:45 | Case report: Challenging Case of Mantle Cell Lymphoma (MCL) Presenting in Leukemic Phase, with A.Fib, GI bleeding: Therapeutic Challenges Presented by: Marwa Tagelsir, UAE |
08:30-08:45 | Doublets vs triplets in older AML patients? Stephane De Botton, France |
| 08:45-09:00 | Q&A | 08:45-09:00 | Which AML and MDS patients should we transplant in 2024? Aditi Shastri, USA |
| 09:00-09:20 | What is new in front-line management? Madiha Iqbal, USA |
09:00-09:15 | What to do with TP53 mutated higher risk MDS/AML? Maximilian Stahl, USA |
| 09:20-09:40 | Management of relapsed and/or refractory MCL: Amer Beitinjaneh, USA |
09:15-09:30 | Targeting novel mechanisms of resistance in AML: Gabriel Ghiaur, USA |
| 09:40-10:00 | Panel discussion: All session faculty | 09:30-09:45 | Should we use maintenance therapy post-transplant? Talha Badar, USA |
| 09:45-10:00 | Panel discussion: All session faculty | ||
| 10:00-10:30 | Coffee Break | ||
| 10:30-12:00 | IACH Session: Management of hard-to-treat patients | ||
| Moderator: Mohamad Mohty, France | |||
| 10:30-10:45 | Management of severe TMA: Iman Abou Dalle, Lebanon |
||
| 10:45-11:00 | Management of severe CRS: Razan Mohty, USA |
||
| 11:00-11:15 | Management of VOD in children: Selim Corbacioglu, Germany |
||
| 11:15-11:30 | Management of VOD in adults: Antonio Pagliuca, UK |
||
| 11:30-12:00 | Panel discussion: All session faculty | ||
| 12:00-12:45 | Lunch Break | ||
| 12:45-14:15 | Session 8a: Rare diseases |
12:45-14:15 | Session 8b: A new era of disease modification for polycythemia vera (PV) |
| Chair: Anna Sureda, Spain | Moderator: Naveen Pemmaraju, USA | ||
| 12:45-13:00 | Case report: About an extraordinary case: fever and pancytopenia of unknown origin in a post-transplant allogenic patient Presented by: Adolfo Fernández Sánchez, Spain |
12:45-13:05 | How can JAK2 VAF be incorporated into management of PV? Adam Mead, UK |
| 13:00-13:15 | Q&A | 13:05-13:25 | What is a high-risk PV patient in 2024? Alberto Alvarez-Larrán, Spain |
| 13:15-13:35 | Post-transplant lymphoproliferative disorders (PTLD): Susan Prockop, USA |
13:25-13:55 | Debate: All low-risk PV patients who are able to tolerate IFN should be offered it Yes: Tiziano Barbui, Italy No: Mary Frances McMullin, UK |
| 13:35-13:55 | Richter’s transformation: Ohad Benjamini, Israel |
13:55-14:15 | Panel discussion: All session faculty |
| 13:55-14:15 | Panel discussion: All session faculty | ||
| 14:15-15:45 | IACH Lectures | ||
| Moderators: Mohamad Mohty, France; Arnon Nagler, Israel | |||
| 14:15-14:35 | Bispecific antibodies in lymphoma: Ali Bazarbachi, Lebanon |
||
| 14:35-14:55 | Update on therapy of elderly myeloma: Thierry Facon, France |
||
| 14:55-15:15 | Cellular therapy in acute leukemia: Fabio Ciceri, Italy |
||
| 15:15-15:45 | Panel discussion: All session faculty + Bhagirathbhai Dholaria, USA |
||
| 15:45-16:00 | Meeting Closing Remarks by the IACH Co-Chairs |
||